Qube Research & Technologies LTD Eli Lilly & CO Call Options Transaction History

Qube Research & Technologies LTD

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $9.13 Million - $11.5 Million	12,600 Added 115.6%	23,500 $21.3 Million
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $6.63 Million - $8.87 Million	-11,200 Reduced 50.68%	10,900 $8.48 Million
Q4 2023 Feb 13, 2024	BUY	$525.19 - $619.13 $11.6 Million - $13.7 Million	22,100 New	22,100 $12.9 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $8.89 Million - $10.1 Million	30,000 New	30,000 $9.7 Million

3,950

763M

6.32M

8.59M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $778B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.